Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in ad-vanced or metastatic gastric or gastroesophageal junction adenocarci-noma.

Schlintl, V; Huemer, F; Greil, R; Weiss, L.
J Gastrointest Oncol. 2021 Apr;12(2):906-909. doi: 10.21037/jgo-20-230.